MediWound Ltd. (MDWD)

Market Cap	189.52M
Revenue (ttm)	20.14M
Net Income (ttm)	-19.97M
Shares Out	10.79M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,462
Open	18.69
Previous Close	18.53
Day's Range	17.53 - 18.77
52-Week Range	7.45 - 24.00
Beta	0.83
Analysts	Strong Buy
Price Target	28.00 (+59.36%)
Earnings Date	Aug 14, 2024

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other ha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: MDWD
• Website: https://www.mediwound.com

Financial Performance

In 2023, MediWound's revenue was $18.69 million, a decrease of -29.48% compared to the previous year's $26.50 million. Losses were -$6.72 million, -65.73% less than in 2022.

Analyst Forecast

According to one analyst, the rating for MDWD stock is "Strong Buy" and the 12-month stock price forecast is $28.0.

Price Target

$28.0

(59.36% upside)

Analyst Consensus: Strong Buy